Haematologica (Jul 2018)

The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project

  • Monica Bellei,
  • Francine M. Foss,
  • Andrei R. Shustov,
  • Steven M. Horwitz,
  • Luigi Marcheselli,
  • Won Seog Kim,
  • Maria E. Cabrera,
  • Ivan Dlouhy,
  • Arnon Nagler,
  • Ranjana H. Advani,
  • Emanuela A. Pesce,
  • Young-Hyeh Ko,
  • Virginia Martinez,
  • Silvia Montoto,
  • Carlos Chiattone,
  • Alison Moskowitz,
  • Michele Spina,
  • Irene Biasoli,
  • Martina Manni,
  • Massimo Federico

DOI
https://doi.org/10.3324/haematol.2017.186577
Journal volume & issue
Vol. 103, no. 7

Abstract

Read online

This analysis explored factors influencing survival of patients with primary refractory and relapsed peripheral T-cell lymphomas enrolled in the prospective International T-cell Project. We analyzed data from 1020 patients with newly diagnosed disease, enrolled between September 2006 and December 2015. Out of 937 patients who received first-line treatment, 436 (47%) were identified as refractory and 197 (21%) as relapsed. Median time from the end of treatment to relapse was 8 months (range 2-73). Overall, 75 patients (8%) were consolidated with bone marrow transplantation, including 12 refractory and 22 relapsed patients. After a median follow up of 38 months (range 1-96 months) from documentation of refractory/relapsed disease, 440 patients had died. The median overall survival (OS) was 5.8 months; 3-year overall survival rates were 21% and 28% for refractory and relapsed patients, respectively (P